Keep pulling the thread on Wendy Barnes.
High consumer and provider demand for GLP-1s created market pressure that led to increased price competition and a narrowing of the list-to-net price gap without new legislation.
Almost one billion prescriptions are left at the pharmacy counter each year in the U.S. due to affordability issues.
Eli Lilly launched a direct-to-consumer program for its GLP-1 drugs to increase consumer access.
Rho is the leading provider of branded GLP-1 drugs in the United States.
Rho has launched the Wagovi pill on its platform and added Eli Lilly's oral GLP-1 to its formulary.
Two years ago, GLP-1 drugs had a list price of $1,300 and were not widely covered by insurance.
Pharmaceutical manufacturers have been hesitant to offer competitive cash prices directly to consumers because they feel they will be punished by payers if they do not use a rebate model to get on formularies.
The TrumpRx drug pricing program was an idea from the Trump administration, not from GoodRx.
Rho declined to offer ADHD medications on its platform due to patient safety concerns, viewing controlled substances as a different category from GLP-1s.
On the Rho platform, an independent medical practice, not Rho itself, determines which conditions are safe and appropriate to be treated via telemedicine.
It is not in the consumer's best interest for pharmaceutical companies to exclusively use their own brand.com direct-to-consumer programs, as patients often take medications from multiple manufacturers.
Rho's platform reaches patients in 99% of primary care deserts in the United States.